Specific inhibitors of the EGFR, BRAF, KRAS, and MEKproteins are included in many standards of anticancer therapy and have provedeffective in the therapy of cancers carrying oncogenic mutations in this axis.However, cancer cells often grow resistance to such inhibitors and ERKreactivation is believed to be one of the reasons for such resistance [8, 9]. This evidence concerns the gene BRAF and cancer.